May 2017

<table>
<thead>
<tr>
<th>Drug</th>
<th>sarilumab (Kevzara)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>Listing request</td>
<td>As per indication</td>
</tr>
<tr>
<td>Dosage form(s)</td>
<td>Pre-filled syringe (150 mg/1.14 mL or 200 mg/1.14 mL)</td>
</tr>
<tr>
<td>NOC Date</td>
<td>January 12, 2017</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Sanofi Genzyme</td>
</tr>
</tbody>
</table>
The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

The statements, findings, conclusions, views, and opinions contained and expressed in this publication are based in part on data obtained under licence from IMS Health Canada Inc. concerning the following information service: DeltaPA. All Rights Reserved. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party data supplier.
TABLE OF CONTENTS

ABBREVIATIONS .................................................................................................................................................. ii
EXECUTIVE SUMMARY ........................................................................................................................................ iii
APPENDIX 1: REVIEWER WORKSHEETS .................................................................................................................. 1
REFERENCES ............................................................................................................................................................. 7

Tables
Table 1: Cost Comparison Table of Biologic Treatments for Rheumatoid Arthritis in Adult Patients ........ vi
Table 2: Summary of Manufacturer’s Submission ..................................................................................................... 1
Table 3: Manufacturer’s Results Comparing the Average Annual Cost of the First Three Years of Sarilumab Therapy With That of Other Biologics for the Treatment of Rheumatoid Arthritis ..... 2
Table 4: CDR’s Results Comparing the Average Annual Cost of the First and Subsequent Years of Sarilumab Therapy With That of Other Biologics for the Treatment of Rheumatoid Arthritis ..... 3
Table 5: Exploratory Analysis Comparing the Annual Cost of Tocilzumab SC With Varying Proportions of Patients Using Weekly Dosing to That of Sarilumab ......................................................... 6
ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR</td>
<td>CADTH Common Drug Review</td>
</tr>
<tr>
<td>DMARD</td>
<td>disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SEB</td>
<td>subsequent entry biologic</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

Background
Sarilumab (Kevzara) for subcutaneous (SC) injection is a fully human immunoglobulin G1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin-6 receptors inhibiting interleukin-6 mediated signalling. It is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs).\(^1\) Sarilumab is available in 150 mg and 200 mg single-use pre-filled syringes for SC injection. The recommended dose of sarilumab is 200 mg SC injection every two weeks, with a reduction to 150 mg every two weeks for management of neutropenia, thrombocytopenia, and elevated liver enzymes. Sarilumab should be given in combination with methotrexate or other conventional DMARD but may be used as monotherapy in cases of intolerance or contraindication to methotrexate or DMARDs.\(^1\) The manufacturer has submitted a price of $700 per pre-filled syringe (for both 150 mg and 200 mg doses) resulting in an annual cost of $18,200 per patient.

Summary of the Economic Analysis Submitted by the Manufacturer
The manufacturer submitted a cost comparison\(^2\) of sarilumab 200 mg to the monograph-recommended doses of other biologic DMARDs used for the treatment of RA in Canada (see Table 1).\(^3\)\(^-\)\(^14\) Clinical similarity among biologics was assumed on the basis of head-to-head trials comparing sarilumab with adalimumab (MONARCH\(^15,16\)) and tocilizumab (ASCERTAIN\(^17\)) as well as an unpublished network meta-analysis.\(^18\)

While the analysis was stated to be from the perspective of a public health care payer (e.g., a provincial Ministry of Health) only drug costs were included in the analysis; all other costs were assumed equal. Drug costs were considered over a three-year time horizon in order to account for dose titration in the first year and two years of maintenance therapy. Drug costs were derived primarily from the Ontario Drug Benefit Formulary and Exceptional Access Program list prices for comparators, the Saskatchewan Formulary for abatacept intravenous (IV), and the manufacturer’s submitted price for sarilumab. No discounting was applied in years 2 and 3. A patient weight of 75 kg was assumed for weight-based comparator dosing. A price for the subsequent entry biologic (SEB) etanercept (Brenzys) was not available at the time of the manufacturer’s analysis, and thus results were not reported.

Key Limitations
Uncertainty in Assumption of Clinical Similarity
Head-to-head trials reported statistically significant and clinically relevant improvements in clinical response, clinical remission, and improvement in physical functioning when sarilumab monotherapy was compared with adalimumab monotherapy\(^15,16\)\(^17\)\(^18\).

The manufacturer-provided network meta-analysis suggested that sarilumab\(^18\) compared with other biologics, including tocilizumab IV and SC,\(^17\),\(^18\) where biologics are used in combination with a conventional DMARD.\(^18\) To other biologics within the network meta-analysis\(^18\) patients with an inadequate response to conventional DMARDs using biologic monotherapy. The CADTH Common Drug Review (CDR) clinical reviewers determined that no conclusion could be drawn regarding the comparative efficacy and safety of
sarilumab versus biologics in patients with an inadequate response to an anti–tumour necrosis factor therapy (see CDR Clinical Report, Appendix 6).

In summary, CDR reviewers have higher confidence in the clinical similarity of sarilumab in combination with conventional DMARDs compared with other biologics plus conventional DMARDs in patients who have an inadequate response to conventional DMARDs alone. The assumption of clinical similarity is less certain between biologic monotherapies or in patients with an inadequate response to anti–tumour necrosis factor therapy.

Presentation of the Results
While an annual average cost of the first three years of therapy has been accepted by CDR in the past, given the potential for biologic treatment for RA to either be discontinued or continue long term, CDR considered this method of presentation of results to be not easily generalized to variations in prescribing patterns in clinical practice. CDR reanalyses instead presented annual and incremental costs for the first year of therapy and then average subsequent years, allowing a better comparison of comparative drug costs, which highlights comparators with loading doses (most often IV therapies). This change had little impact on the cost of sarilumab relative to its comparators.

New Comparator Pricing Available
At the time of the manufacturer’s analysis, no public price was available for SEB etanercept. However, a wholesale price of $305 per 50 mg pre-filled syringe of SEB etanercept ($15,860 per patient annually) was available at the time of the CDR review, which is $2,340 less expensive per patient per year than sarilumab.

Issues for Consideration
Monitoring Costs Excluded
Treatment with interleukin-6 inhibitors is associated with an increased risk of neutropenia, thrombocytopenia, elevated liver enzymes, and increased lipid levels; therefore, routine monitoring of neutrophils, platelets, and liver enzymes is recommended. In contrast, anti–tumour necrosis factor biologic monographs recommend routine monitoring only for infection. Should treatment with sarilumab (or tocilizumab) result in increased laboratory testing, this would increase incremental costs (or decrease incremental savings) relative to anti–tumour necrosis factor therapies.

Potential for Off-Label Escalated Dosing
While the sarilumab product monograph contains no approved dose escalation and a dose-ranging trial showed no additional benefit with 150 mg weekly dosing compared with 150 mg or 200 mg biweekly, the expert consulted by CDR considered it possible that some patients who partially respond to initial sarilumab treatment might receive more frequent dosing, which would increase costs relative to biologics, which either are not typically escalated when treating RA in clinical practice according to experts consulted by CDR (e.g., adalimumab) or have already taken escalation into account (e.g., tocilizumab).

Publicly Available List Prices May Not Reflect Actual Costs to Public Plans
The actual costs paid by Canadian public drug plans for biologic treatments for RA are likely lower than those listed on publicly available formularies, which reduces the relative attractiveness of the submitted price of sarilumab.
Results / Conclusions
When compared with the most widely used biologics for the treatment of RA, sarilumab ($18,200 per patient per year) is less expensive than adalimumab ($20,019 per patient per year) and branded etanercept (21,108 per patient per year), but more expensive than the newly introduced SEB etanercept ($15,860 per patient per year). A price reduction of 13% would be required for sarilumab to be cost-neutral to SEB etanercept.

When compared with tocilizumab, the other interleukin-6 inhibitor, sarilumab is more expensive than the tocilizumab IV formulation ($9,402 to $17,629 per patient per year) and biweekly tocilizumab SC use ($9,230 per patient per year) but similar to weekly tocilizumab SC use ($18,460 per patient per year). In order for sarilumab to be cost-neutral to a weighted average cost of tocilizumab SC, 97% of patients would need to be using weekly versus biweekly doses of tocilizumab. Where more than 3% of patients are receiving tocilizumab biweekly, price reductions for sarilumab would be required for cost neutrality (see APPENDIX 1).

Cost Comparison Table
Clinical experts have deemed the comparator treatments presented in Table 1 to be appropriate. Comparators may be recommended (appropriate) practice versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures. Existing Product Listing Agreements are not reflected in Table 1 and as such may not represent the actual costs to public drug plans.
**TABLE 1: COST COMPARISON TABLE OF BIOLOGIC TREATMENTS FOR RHEUMATOID ARTHRITIS IN ADULT PATIENTS**

<table>
<thead>
<tr>
<th>Comparators</th>
<th>Strength</th>
<th>Dose Form</th>
<th>Price ($)</th>
<th>Recommended Dose</th>
<th>Annual Drug Cost ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarilumab (Kevzara)</td>
<td>150 mg/1.14 mL</td>
<td>Pre-filled syringe</td>
<td>700.0000&lt;sup&gt;a&lt;/sup&gt;</td>
<td>200 mg SC every two weeks</td>
<td>18,200</td>
</tr>
<tr>
<td>Abatacept SC (Orencia)</td>
<td>125 mg/mL</td>
<td>Pre-filled syringe</td>
<td>366.1000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>125 mg weekly&lt;sup&gt;c&lt;/sup&gt;</td>
<td>19,037</td>
</tr>
<tr>
<td>Abatacept IV (Orencia)</td>
<td>250 mg/15 mL</td>
<td>Vial</td>
<td>490.0500&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Patients &lt; 60 kg: 500 mg Patients 60 to 100 kg: 750 mg Patients &gt; 100 kg: 1,000 mg 500 to 1,000 mg at weeks 0, 2, and 4 then every 4 weeks</td>
<td>Year 1: 20,582 Thereafter: 19,112</td>
</tr>
<tr>
<td>Adalimumab SC (Humira)</td>
<td>40 mg/0.8 mL</td>
<td>Pre-filled syringe or pen</td>
<td>769.9700</td>
<td>40 mg every other week</td>
<td>20,019</td>
</tr>
<tr>
<td>Anakinra (Kinere)</td>
<td>100 mg</td>
<td>Pre-filled syringe</td>
<td>48.0571</td>
<td>100 mg daily</td>
<td>17,493</td>
</tr>
<tr>
<td>Certolizumab pegol (Cimzia)</td>
<td>200 mg/mL</td>
<td>Pre-filled syringe</td>
<td>664.5100</td>
<td>400 mg at weeks 0, 2 and 4 then 200 mg every 2 weeks</td>
<td>Year 1: 19,271 Thereafter: 17,277</td>
</tr>
<tr>
<td>Etanercept (Enbrel)</td>
<td>25 mg</td>
<td>Vial</td>
<td>202.9300</td>
<td>50 mg weekly or two 25 mg doses on same day every week or every 3 or 4 days</td>
<td>21,105</td>
</tr>
<tr>
<td></td>
<td>50 mg/mL</td>
<td>Pre-filled syringe or auto-injector</td>
<td>405.9850</td>
<td></td>
<td>21,111</td>
</tr>
<tr>
<td>Entanercept (Brenzys)</td>
<td>50 mg/mL</td>
<td>Pre-filled syringe</td>
<td>305.0000&lt;sup&gt;g&lt;/sup&gt;</td>
<td>50 mg weekly</td>
<td>15,860</td>
</tr>
<tr>
<td>Golimumab SC (Simponi)</td>
<td>50 mg/0.5 mL</td>
<td>Pre-filled syringe or auto-injector</td>
<td>1,555.17</td>
<td>50 mg monthly</td>
<td>18,662</td>
</tr>
<tr>
<td>Golimumab IV (Simponi)</td>
<td>50 mg/4 mL</td>
<td>Vial</td>
<td>849.5000&lt;sup&gt;g&lt;/sup&gt;</td>
<td>2 mg/kg at weeks 0 and 4, then every 8 weeks thereafter</td>
<td>Year 1: 17,829 Thereafter: 16,565</td>
</tr>
</tbody>
</table>

*Note: Price and recommended dose may vary based on patient demographics and medical history.*
<table>
<thead>
<tr>
<th>Comparators</th>
<th>Strength</th>
<th>Dose Form</th>
<th>Price ($)</th>
<th>Recommended Dose</th>
<th>Annual Drug Cost ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab (Remicade)</td>
<td>100 mg</td>
<td>Vial</td>
<td>987.5600</td>
<td>3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. Depending on clinical response, dose can be increased to 10 mg/kg and/or up to every four weeks</td>
<td>Year 1: 23,701</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thereafter: 19,257</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 mg/kg every 4 weeks: $102,706 yearly</td>
</tr>
<tr>
<td>Infliximab (Inflectra)</td>
<td>100 mg</td>
<td>Vial</td>
<td>525.0000</td>
<td></td>
<td>Year 1: 12,600 b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thereafter: 10,238 b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10 mg/kg every 4 weeks: $54,600 annually b</td>
</tr>
<tr>
<td>Rituximab (Rituxan)</td>
<td>100 mg/10 mL, 500 mg/50 mL</td>
<td>Vial</td>
<td>466.3200, 2,331.61</td>
<td>A course consists of 1,000 mg infusions at weeks 0 and 2. Reassess for retreatment at week 26, no sooner than 16 weeks after previous</td>
<td>18,653 assumes 2 courses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Per course: 9,326</td>
</tr>
<tr>
<td>Tocilizumab SC (Actemra)</td>
<td>162 mg/0.9 mL</td>
<td>Pre-filled syringe</td>
<td>355.0000</td>
<td>Patients &lt; 100 kg: 162 mg SC every two weeks, increasing to weekly based on clinical response. Patients ≥ 100 kg: 162 mg SC weekly</td>
<td>Every two weeks: 9,230</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weekly: 18,460</td>
</tr>
<tr>
<td>Tocilizumab IV (Actemra)</td>
<td>80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL</td>
<td>Vial</td>
<td>180.8100, 452.0300, 904.0600</td>
<td>4 mg/kg every 4 weeks followed by an increase to 8 mg/kg based on clinical response</td>
<td>4 mg/kg: 10,577 b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 mg/kg: 17,629 b</td>
</tr>
<tr>
<td>Tofacitinib (Xeljanz)</td>
<td>5 mg</td>
<td>Tablet</td>
<td>23.5585</td>
<td>5 mg p.o. twice daily</td>
<td>17,151</td>
</tr>
</tbody>
</table>

IV = intravenous; p.o. = orally; SC = subcutaneous.

a Manufacturer’s submitted price.
b Saskatchewan Formulary list price (January 2017).
c Abatacept-naive patients require a single weight-based loading dose of 500, 750, or 1,000 mg intravenous abatacept, with weekly SC injections to start within one day thereafter, not included in cost.
d IMS Quintiles Delta PA wholesale price (January 2017), also the price submitted to the CDR.

Source: Ontario Drug Benefit Formulary or Exceptional Access Program (January 2017) list prices unless otherwise indicated. Patient weight assumed to be 75 kg. Excess medication in vials is assumed wasted. Annual period assumes 52 weeks, 26 x 2 weeks, 13 x 4 weeks, or 364 days per year.
APPENDIX 1: REVIEWER WORKSHEETS

### Table 2: Summary of Manufacturer’s Submission

<table>
<thead>
<tr>
<th>Drug Product</th>
<th>Sarilumab (Kevzara)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Sarilumab 200 mg every 2 weeks with conventional DMARD therapy, 15% of patients reducing to 150 mg every 2 weeks for management of neutropenia, thrombocytopenia, and elevated liver enzymes</td>
</tr>
<tr>
<td>Comparators</td>
<td>With conventional DMARDs:</td>
</tr>
<tr>
<td></td>
<td>- Anakinra</td>
</tr>
<tr>
<td></td>
<td>- Abatacept IV or SC</td>
</tr>
<tr>
<td></td>
<td>- Adalimumab</td>
</tr>
<tr>
<td></td>
<td>- Certolizumab pegol</td>
</tr>
<tr>
<td></td>
<td>- Etanercept (branded or SEB)</td>
</tr>
<tr>
<td></td>
<td>- Golimumab IV or SC</td>
</tr>
<tr>
<td></td>
<td>- Infliximab (branded or SEB)</td>
</tr>
<tr>
<td></td>
<td>- Rituximab</td>
</tr>
<tr>
<td></td>
<td>- Tocilizumab IV or SC</td>
</tr>
<tr>
<td></td>
<td>- Tofacitinib</td>
</tr>
<tr>
<td>Study Question</td>
<td>From the perspective of a Canadian public payer, what is the incremental cost of sarilumab compared with other biologic DMARDs and targeted synthetic DMARD in patients with rheumatoid arthritis and who have an inadequate response or are intolerant to one or more biologic or non-biologic DMARDs?</td>
</tr>
<tr>
<td>Type of Economic Evaluation</td>
<td>Cost comparison</td>
</tr>
<tr>
<td>Target Population</td>
<td>Adults with rheumatoid arthritis who have an inadequate response or are intolerant to one or more biologic or non-biologic DMARDs</td>
</tr>
<tr>
<td>Perspective</td>
<td>Public payer</td>
</tr>
<tr>
<td>Outcome Considered</td>
<td>Average annual drug cost of first 3 years of therapy</td>
</tr>
<tr>
<td>Key Data Sources</td>
<td>ODB list prices, Saskatchewan Formulary list prices</td>
</tr>
<tr>
<td>Clinical Efficacy</td>
<td>MONARCH and ASCERTAIN trials and manufacturer sponsored NMA</td>
</tr>
<tr>
<td>Harms</td>
<td>ASCERTAIN trial and NMA</td>
</tr>
<tr>
<td>Time Horizon</td>
<td>3 years (with 1 year equalling 364 days); no discount applied</td>
</tr>
<tr>
<td>Results for Base Case</td>
<td>Sarilumab had an average cost of $18,200 per year over three years of therapy, which was more expensive than that of anakinra, certolizumab, golimumab IV, standard doses of infliximab SEB, tocilizumab IV and standard dose SC, and tofacitinib, but less than abatacept, adalimumab, etanercept, golimumab SC, branded infliximab, high-dose SEB infliximab, and high-dose tocilizumab SC.</td>
</tr>
</tbody>
</table>

DMARD = disease-modifying antirheumatic drug; IV = intravenous; NMA = network meta-analysis; ODB = Ontario Drug Benefit Formulary; SC = subcutaneous; SEB = subsequent entry biologic.
Manufacturer’s Results

In the manufacturer’s base case, and at the submitted price of $700 per 150 mg or 200 mg syringe, the average annual cost of sarilumab over the first three years of therapy for rheumatoid arthritis (RA) was $18,200 per patient, while the average annual cost of the first three years of therapy with other biologics ranged from $9,326 to $21,108 per patient ($101,719 per patient if the highest recommended dose of infliximab is included). Thus, the incremental cost of sarilumab therapy ranged from a savings of $2,907 per patient per year to an additional cost of $8,874 per patient per year over the first three years of therapy. See Table 3 for details. The cost of subsequent entry biologic (SEB) etanercept was not available at the time of the manufacturer’s analysis.

**Table 3: Manufacturer's Results Comparing the Average Annual Cost of the First Three Years of Sarilumab Therapy With That of Other Biologics for the Treatment of Rheumatoid Arthritis**

<table>
<thead>
<tr>
<th>Comparator</th>
<th>3-Year Average Annual Cost ($)</th>
<th>Incremental Cost (Savings) of Sarilumab vs. Comparator ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarilumab (Kevzara)</td>
<td>18,200.00</td>
<td>Reference</td>
</tr>
<tr>
<td>Anakinra (Kineret)</td>
<td>17,492.78</td>
<td>707.22</td>
</tr>
<tr>
<td>Abatacept IV (Orencia IV)</td>
<td>19,602.00</td>
<td>(1,402.00)</td>
</tr>
<tr>
<td>Abatacept SC (Orencia SC)</td>
<td>19,509.82</td>
<td>(1,309.82)</td>
</tr>
<tr>
<td>Adalimumab (Humira)</td>
<td>20,019.22</td>
<td>(1,819.22)</td>
</tr>
<tr>
<td>Certolizumab (Cimzia)</td>
<td>18,163.27</td>
<td>36.73</td>
</tr>
<tr>
<td>Etanercept (Enbrel)</td>
<td>21,107.97</td>
<td>(2,907.97)</td>
</tr>
<tr>
<td>Etanercept SEB (Brenzys)</td>
<td>Price not available at time of analysis</td>
<td>Not available</td>
</tr>
<tr>
<td>Golimumab IV (Simponi IV)</td>
<td>16,540.00</td>
<td>1,660.00</td>
</tr>
<tr>
<td>Golimumab SC (Simponi SC)</td>
<td>18,662.04</td>
<td>(462.04)</td>
</tr>
<tr>
<td>Infliximab (Remicade)</td>
<td>3 mg/kg 10 mg/kg</td>
<td>(1,551.20)</td>
</tr>
<tr>
<td></td>
<td>10 mg/kg</td>
<td>(83,518.68)</td>
</tr>
<tr>
<td>Infliximab SEB (Inflectra)</td>
<td>10,500.00</td>
<td>7,700.00</td>
</tr>
<tr>
<td></td>
<td>54,075.00</td>
<td>(35,875.00)</td>
</tr>
<tr>
<td>Rituximab (Rituxan)</td>
<td>1 course 2 courses</td>
<td>8,873.59</td>
</tr>
<tr>
<td></td>
<td>9,326.41 18,652.83</td>
<td>(452.83)</td>
</tr>
<tr>
<td>Tocilizumab IV (Actemra IV)</td>
<td>9,402.12</td>
<td>8,797.88</td>
</tr>
<tr>
<td></td>
<td>4 mg/kg 8 mg/kg</td>
<td>1,414.63</td>
</tr>
<tr>
<td>Tocilizumab SC (Actemra SC)</td>
<td>Q2W QW</td>
<td>8,970.00</td>
</tr>
<tr>
<td></td>
<td>9,230.00 18,460.00</td>
<td>(260.00)</td>
</tr>
<tr>
<td>Tofacitinib (Xeljanz)</td>
<td>17,150.59</td>
<td>1,049.41</td>
</tr>
</tbody>
</table>

IV = intravenous; Q2W = every two weeks; QW = weekly; SC = subcutaneous; SEB = subsequent entry biologic; vs. = versus.

Table 1 unit costs and dosing. Average annual cost includes the first three years of therapy divided by three and does not include dispensing fees, administration fees, markups, or discounting. Patient weight assumed to be 75 kg. Excess medication in vials was assumed to be wasted.

The manufacturer concluded that sarilumab for RA was more expensive than anakinra, certolizumab, golimumab intravenous (IV), infliximab SEB, rituximab, tocilizumab biweekly, and tofacitinib, but less expensive than abatacept, adalimumab, etanercept, golimumab subcutaneous (SC), tocilizumab weekly, and branded infliximab.

The manufacturer also provided results for patients weighing 50 kg and 100 kg. As sarilumab dosing and thus cost does not vary by weight, it became relatively more expensive when patients weighed 50 kg...
and relatively less expensive when patients weighed 100 kg when compared with biologics with weight-based dosing such as abatacept IV, golimumab IV, infliximab, and tocilizumab IV.

In addition, the manufacturer conducted sensitivity analyses across all three assumed patient weights incorporating the World Health Organization Defined Daily Dose for each comparator, an annual compliance rate of 80%, the exclusion of drug wastage, and including markups and dispensing fees. These analyses altered the absolute costs of sarilumab and comparators but not the conclusion that the cost of sarilumab is within the range of biologic comparators for the treatment of adults with RA.

**CADTH Common Drug Review Results**
The CADTH Common Drug Review (CDR) reviewers considered the manufacturer’s list of comparators to be appropriate with the addition of a newly available public price for etanercept SEB. However, rather than presenting an average annual drug costs over the first three years of therapy, given the unknown and potentially long-term length of therapy, CDR reviewers considered it more appropriate to present the comparative drug costs of the first and average subsequent years of therapy separately. Results remained similar to the manufacturer’s (see Table 4), although as several IV comparators are less expensive in subsequent years than the first (which includes loading doses), the overall incremental drug cost of sarilumab is increased (or incremental savings decreased) the longer a patient remains on therapy.

The annual drug cost of sarilumab is $2,340 more per patient than that of SEB etanercept ($15,860 per patient).

**Table 4: CDR’s Results Comparing the Average Annual Cost of the First and Subsequent Years of Sarilumab Therapy With That of Other Biologics for the Treatment of Rheumatoid Arthritis**

<table>
<thead>
<tr>
<th>Comparator</th>
<th>First Year</th>
<th>Incremental Cost (Savings) of Sarilumab vs. Comparator ($)</th>
<th>Average Annual Cost Thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost ($)</td>
<td></td>
<td>Cost ($)</td>
</tr>
<tr>
<td>Sarilumab (Kevzara)</td>
<td>18,200.00</td>
<td>Reference</td>
<td>18,200.00</td>
</tr>
<tr>
<td>Anakinra (Kineret)</td>
<td>17,492.78</td>
<td>707.22</td>
<td>17,492.78</td>
</tr>
<tr>
<td>Abatacept IV (Orencia IV)</td>
<td>20,582.10</td>
<td>(2,382.10)</td>
<td>19,111.95</td>
</tr>
<tr>
<td>Abatacept SC (Orencia SC)</td>
<td>20,455.05</td>
<td>(2,255.05)</td>
<td>19,037.20</td>
</tr>
<tr>
<td>Adalimumab (Humira)</td>
<td>20,019.22</td>
<td>(1,819.22)</td>
<td>20,019.22</td>
</tr>
<tr>
<td>Certolizumab (Cimzia)</td>
<td>19,935.30</td>
<td>(1,735.30)</td>
<td>17,277.26</td>
</tr>
<tr>
<td>Etanercept (Enbrel)</td>
<td>21,107.97</td>
<td>(2,907.97)</td>
<td>21,107.97</td>
</tr>
<tr>
<td>Etanercept SEB (Brenzys)</td>
<td>15,860.00</td>
<td>2,340.00</td>
<td>15,860.00</td>
</tr>
<tr>
<td>Golimumab IV (Simponi IV)</td>
<td>17,367.00</td>
<td>833.00</td>
<td>16,126.50</td>
</tr>
<tr>
<td>Golimumab SC (Simponi SC)</td>
<td>18,662.04</td>
<td>(462.04)</td>
<td>18,662.04</td>
</tr>
<tr>
<td>Infliximab (Remicade)</td>
<td>23,701.44</td>
<td>(5,501.44)</td>
<td>17,776.08</td>
</tr>
<tr>
<td>Infliximab SEB (Inflectra)</td>
<td>12,600.00</td>
<td>(34,825.00)</td>
<td>9,450.00</td>
</tr>
<tr>
<td>Rituximab (Rituxan)</td>
<td>9,326.42</td>
<td>8,873.58</td>
<td>9,326.42</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>9,402.12</td>
<td>8,797.88</td>
<td>9,402.12</td>
</tr>
</tbody>
</table>
Of particular interest is the comparison of sarilumab to adalimumab and etanercept, the most prescribed anti–tumour necrosis factors for the treatment of RA, and tocilizumab, an interleukin-6 inhibitor like sarilumab. Both adalimumab and tocilizumab IV were compared with sarilumab in head-to-head trials, in MONARCH and ASCERTAIN, respectively.

In MONARCH, sarilumab monotherapy showed a statistically significant and clinically meaningful clinical response, clinical remission, and improvement in physical functioning compared with adalimumab monotherapy, with a similar proportion of patients experiencing at least one serious adverse event and withdrawing due to adverse events (see CDR Clinical Report, sections 3.5 and 3.6). At the submitted price, sarilumab is less expensive than the list price of adalimumab.

ASCERTAIN was a small safety study comparing sarilumab plus conventional disease-modifying antirheumatic drugs (DMARDs) with tocilizumab IV plus conventional DMARDs in patients with an inadequate response or intolerance to anti–tumour necrosis factor therapy. Efficacy outcomes were considered exploratory, and statistical analyses were not conducted. There were higher rates of discontinuation due to adverse events in the sarilumab group (15.7%) compared with tocilizumab IV (3.9%), as well as, although given the small size of the trial, these conclusions are uncertain.

At the submitted price, sarilumab ($18,200 per patient per maintenance year) is more expensive than tocilizumab IV at either the 4 mg/kg or 8 mg/kg every four week dosing schedule ($9,402 to $17,629 per patient per maintenance year). Sarilumab is also more expensive than biweekly tocilizumab SC at the listed price ($9,230 per patient) but slightly less expensive than weekly tocilizumab SC ($18,460 per patient). Thus the relative cost of sarilumab compared with tocilizumab SC depends on the proportion of patients using weekly versus biweekly tocilizumab SC. In ASCERTAIN, of patients in the tocilizumab IV arm escalated treatment from 4 mg/kg to 8 mg/kg every four weeks, although the majority of them did so at much earlier than escalation would be likely to occur in clinical practice. The proportion of patients escalating tocilizumab SC in clinical practice in Canada is unknown; the clinical expert consulted by CDR roughly estimated that between 50% and 75% of patients continuing on tocilizumab SC eventually escalate to weekly dosing, though it would be unlikely to occur before 12 weeks of therapy in order to assess clinical response to initial dosing.
CDR conducted an exploratory analysis to compare the annual cost of sarilumab therapy with that of the weighted average cost of tocilizumab, assuming a varying proportion of patients using weekly as opposed to biweekly dosing. At the submitted price, sarilumab is more expensive than tocilizumab SC unless more than 97% or more of tocilizumab SC patients are using weekly dosing (see TABLE 5.) Additionally, CDR calculated the percentage price reduction required for sarilumab to be cost-neutral to tocilizumab SC across the all proportions of patients using weekly tocilizumab dosing. For example, if the approximately [ ] of tocilizumab IV patients who escalated to 8 mg/kg dosing in the ASCERTAIN trial is assumed to be a reasonable proxy for tocilizumab SC escalation in clinical practice, then a price [ ] would be necessary for the annual cost of sarilumab to be cost-neutral to the weighted average cost of tocilizumab SC.

While no head-to-head data exist comparing sarilumab with etanercept, the manufacturer’s network meta-analysis [ ] sarilumab and other biologics for the treatment of RA, although limitations exist (see CDR Clinical Report Appendix 6). At the submitted price, the annual cost of sarilumab is $2,908 less than that of branded etanercept but $2,340 per patient per year more than SEB etanercept. Should etanercept SEB displace branded etanercept in clinical practice, a price reduction of 13% would be necessary for the annual cost of sarilumab to be cost-neutral to etanercept.
### Table 5: Exploratory Analysis Comparing the Annual Cost of Tocilizumab SC With Varying Proportions of Patients Using Weekly Dosing to That of Sarilumab

<table>
<thead>
<tr>
<th>Annual Maintenance Cost</th>
<th>Proportion of Tocilizumab SC Patients Using Weekly Dosing (vs. Biweekly)</th>
<th>0%</th>
<th>10%</th>
<th>20%</th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
<th>60%</th>
<th>70%</th>
<th>80%</th>
<th>90%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarilumab</td>
<td>$18,200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average cost</td>
<td>$9,230</td>
<td>$10,153</td>
<td>$11,076</td>
<td>$11,999</td>
<td>$12,922</td>
<td>$13,845</td>
<td>$14,768</td>
<td>$15,691</td>
<td>$16,614</td>
<td>$17,537</td>
<td>$18,460</td>
<td></td>
</tr>
<tr>
<td>Tocilizumab SC</td>
<td>$10,153</td>
<td>$11,076</td>
<td>$11,999</td>
<td>$12,922</td>
<td>$13,845</td>
<td>$14,768</td>
<td>$15,691</td>
<td>$16,614</td>
<td>$17,537</td>
<td>$18,460</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incremental cost (savings) of sarilumab compared with tocilizumab SC</td>
<td>$8,970</td>
<td>$8,047</td>
<td>$7,124</td>
<td>$6,201</td>
<td>$5,278</td>
<td>$4,355</td>
<td>$3,432</td>
<td>$2,509</td>
<td>$1,586</td>
<td>$663</td>
<td>($260)</td>
<td></td>
</tr>
<tr>
<td>Percentage price reduction for sarilumab to be cost-neutral to weighted average tocilizumab SC cost</td>
<td>49%</td>
<td>44%</td>
<td>39%</td>
<td>34%</td>
<td>29%</td>
<td>24%</td>
<td>19%</td>
<td>14%</td>
<td>9%</td>
<td>4%</td>
<td>Not applicable</td>
<td></td>
</tr>
</tbody>
</table>

SC = subcutaneous; vs. = versus.
Patients are assumed to be on the regular or escalated dose of tocilizumab SC for all 52 weeks of the calculated year.
REFERENCES

1. PrKEVZARA™ (sarilumab): solution for subcutaneous injection. 150 mg/1.14 mL or 200 mg/1.14 mL solution in a single-dose pre-filled syringe [product monograph]. Laval (QC): Sanofi-aventis Canada Inc; 2016 Jan 28.
3. PrHumira® (adalimumab): 40 mg in 0.8 mL sterile solution (50 mg/mL) subcutaneous injection [product monograph]. St-Laurent (QC): AbbVie Corporation; 2016 Apr 6.
8. PrActemra® (tocilizumab): 20 mg/mL concentrate solution for infusion; 162 mg/0.9 mL solution for injection [product monograph]. Mississauga (ON): Hoffmann-La Roche Limited; 2016 Jul 12.
11. PrSimponi® (golimumab): solution for injection 50 mg/0.5 mL, 100 mg/1.0 mL, PrSimponi® I.V. (golimumab): solution for infusion 50 mg/4.0 mL [product monograph]. Toronto (ON): Janssen Inc.; 2016 Aug 8.
14. PrOrencia® (abatacept): intravenous infusion, 250 mg/15 mL vial; solution for subcutaneous injection, 125 mg/mL [product monograph]. Montreal (QC): Bristol-Myers Squibb Canada; 2016 Apr 7.


